SURVEILLANCE VS. SURGERY:
New Research Provides Promising Answers for Patients with Pancreatic Cysts

Researchers at Johns Hopkins University School of Medicine, led by The Lustgarten Foundation’s Distinguished Scholar Bert Vogelstein, M.D., identified a panel of molecular markers and clinical features that show promise for classifying pancreatic cysts and determining which cysts require surgery, and those which require surveillance only, according to a study funded by The Lustgarten Foundation and published in the November 2015 issue of the prestigious journal Gastroenterology.

The purpose of this study was to determine whether the molecular genetic features of pancreatic cyst fluid could be used to accurately classify cysts and identify the cysts that require surgical resection to remove them. Results demonstrated that the researchers were able to correctly identify the type of cyst. Seventy-four of the 130 patients had cysts, which in retrospect could have been monitored. Ninety-one percent of these patients – 67 out of 74 patients – were correctly identified by the molecular markers.

“These results are very exciting and extremely promising, and we hope to have something to help patients that’s better than what we currently have so they can avoid unnecessary surgery,” said Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine and Surgery and Director, Multidisciplinary Pancreatic Cyst Program, Johns Hopkins University School of Medicine. “This is a huge step forward.”

The researchers conducted this multi-center, retrospective study using cyst fluid from 130 patients with resected pancreatic cysts. Researchers analyzed the cyst fluid to identify factors including subtle mutations in one dozen genes known to be mutated in pancreatic cysts. The analyses were performed using specialized technologies, and a sophisticated model called MOCA was used to choose markers that could classify the cysts.

Researchers focused on four of the most common types of pancreatic cysts (abbreviated as SCAs, SPNs, MCNs, and IPMNs). The markers were specific for each cyst type, and each cyst had its own molecular profile as well to make the diagnosis more accurate. Using this molecular marker panel, researchers correctly identified 67 of the 74 patients who had surgery but who, in retrospect, didn’t require surgery at that point in time. This panel, therefore, has the potential to lower the number of unnecessary surgeries by an overwhelming 91 percent. This more specific panel of markers is likely to provide physicians with additional information to help them decide whether surgery or surveillance is the most appropriate course of action for their patients, based on the type of mutation they see in a

continued on page 3
Director’s Message

Letter from the Executive Director: Kerri Kaplan

On behalf of everyone at The Lustgarten Foundation, I would like to thank our researchers, constituents, friends, and donors for helping us to raise more than $625,000 for our year-end Milestones & Momentum campaign, significantly surpassing our $500,000 goal. By supporting us so generously, we will be able to fund even more promising pancreatic cancer studies in 2016.

As part of our commitment to research, this issue highlights noteworthy research from Johns Hopkins University that provides promising answers for patients with pancreatic cysts. We also feature the innovative work being conducted by our esteemed panel of Research Investigators, who are pursuing critical areas such as early detection, new methods of drug delivery, and new treatments. They presented their research updates at our recent annual scientific meeting, and their results to date provide renewed hope for early detection and more effective therapies for pancreatic cancer. In addition to The Lustgarten Foundation funded researchers, our collaboration with Stand Up To Cancer has led to the creation of two new pancreatic cancer research teams that are ready to tackle the disease using novel approaches.

We also feature the inspirational stories of Howard Ebert, an eight-year pancreatic cancer survivor, and the late Patricia Galgan, who generously gifted a large portion of her estate to the Foundation, in our Patient and Donor Spotlights.

Additionally, our events and Pancreatic Cancer Research Walks are off to a running start. We have more than 35 walks planned for 2016, including six new walk locations in Colorado, Ohio, Missouri, Texas, California and Kentucky, and hundreds of local events are also scheduled. We hope you’ll join us or consider starting an event or a walk in your area! In addition to these community events, in December we held our 15th Holiday Rock & Roll Bash, our premier annual benefit, which garnered $2 million in donations for the second consecutive year. This event was followed by our 4th annual Party With A Purpose cocktail reception in January, which raised more than $112,000 for research.

With so many fundraising events and research projects planned, 2016 represents a turning point for The Lustgarten Foundation, as we are on the cusp of significant scientific breakthroughs that will accelerate a path towards a cure. These developments would not be possible without the significant contributions of our friends. As always, we thank you for your ongoing support. By joining the fight, you are helping to find a cure.

Warm regards,

Kerri Kaplan
Executive Director and Chief Operating Officer

---

STAFF LEADERSHIP

Robert F. Vizza, Ph.D.
President and Chief Executive Officer
Kerri Kaplan
Executive Director and Chief Operating Officer

Sir Howard Stringer
Retired Chairman of the Board
Sony Corporation

Robert C. Wright
Retired Vice Chairman of the Board and Executive Officer
General Electric

Ronald M. Evans, Ph.D.
Co-founder
IAC/InterActiveCorp

David A. Tuveson, M.D., Ph.D.
Director of Research

David Paul Kelsen, M.D.
Memorial Sloan Kettering Cancer Center

Robert J. Mayer, M.D.
Dana-Farber Cancer Institute & Harvard Medical School

Bruce Stillman, Ph.D.
Cold Spring Harbor Laboratory

Bert Vogelstein, M.D.
The Johns Hopkins University School of Medicine

Christine Ardito-Abraham, Ph.D.
Research Program Manager

STAFF LEADERSHIP

Robert F. Vizza, Ph.D.
President and Chief Executive Officer
Kerri Kaplan
Executive Director and Chief Operating Officer

Sir Howard Stringer
Retired Chairman of the Board
Sony Corporation

Robert C. Wright
Retired Vice Chairman of the Board and Executive Officer
General Electric

Ronald M. Evans, Ph.D.
Co-founder
IAC/InterActiveCorp

David A. Tuveson, M.D., Ph.D.
Director of Research

David Paul Kelsen, M.D.
Memorial Sloan Kettering Cancer Center

Robert J. Mayer, M.D.
Dana-Farber Cancer Institute & Harvard Medical School

Bruce Stillman, Ph.D.
Cold Spring Harbor Laboratory

Bert Vogelstein, M.D.
The Johns Hopkins University School of Medicine

Christine Ardito-Abraham, Ph.D.
Research Program Manager

STAFF LEADERSHIP

Robert F. Vizza, Ph.D.
President and Chief Executive Officer
Kerri Kaplan
Executive Director and Chief Operating Officer

Sir Howard Stringer
Retired Chairman of the Board
Sony Corporation

Robert C. Wright
Retired Vice Chairman of the Board and Executive Officer
General Electric

Ronald M. Evans, Ph.D.
Co-founder
IAC/InterActiveCorp

David A. Tuveson, M.D., Ph.D.
Director of Research

David Paul Kelsen, M.D.
Memorial Sloan Kettering Cancer Center

Robert J. Mayer, M.D.
Dana-Farber Cancer Institute & Harvard Medical School

Bruce Stillman, Ph.D.
Cold Spring Harbor Laboratory

Bert Vogelstein, M.D.
The Johns Hopkins University School of Medicine

Christine Ardito-Abraham, Ph.D.
Research Program Manager

E llen Zimmerman
Newsletter Editor and Communications Associate
particular cyst. Avoiding unnecessary pancreas surgery is important, as the mortality rate from a Whipple procedure, which involves removal of part of the pancreas, a portion of the small intestine, and the gallbladder, is 1-2 percent in the best centers, increasing to over 10 percent in centers where surgeons perform very few of these procedures.

**Directions for Further Research**

Pancreatic cysts are a common occurrence. In fact, 3%-13% of people will have pancreatic cysts show up in a CT scan or an MRI, demonstrating the significant need for determining the cyst type and evaluating whether surgery or surveillance is the best course of action. While this study closely examined four common types of pancreatic cysts, further larger studies, which include other cyst types, are necessary to validate these results. These studies are currently ongoing, with results anticipated in late 2016. According to Dr. Lennon, she and other researchers at Johns Hopkins are comparing their methods for identifying cysts to the current standard of care for cyst identification, which involves imaging and cyst fluid analysis, in an attempt to address how their molecular marker panel can factor into current care in a cost-effective, appropriate manner that provides significant benefits to patients. This research has the potential to impact patients faced with the difficult, and sometimes daunting, choice of whether or not to undergo surgical resection and provides physicians with another valuable tool to aid in the early detection of pancreatic cancer. Most importantly, this research represents a step forward in converting science into clinical practice.

---

**THE LUSTGARTEN FOUNDATION AWARDED $5,000 RESEARCH GRANT**

The Lustgarten Foundation was recently named a finalist in the DSW Designer Shoe Warehouse’s Shoe Lovers Care Leave Your Mark program, earning a $5,000 grant for our research efforts. Leave Your Mark is a philanthropic program that allows DSW’s employees nationwide to nominate nonprofits they feel passionate about supporting. Thank you to all of our constituents, donors, and friends who voted for us!
Dear Friends,

The Lustgarten Foundation recently brought together the respected members of our Scientific Advisory Board, as well as our Distinguished Scholar and Research Investigator grant recipients. The researchers provided in-depth updates into their projects, and we are pleased to highlight some of their advancements below:

**Early Detection and Risk Factors**

- **Dr. Alison Klein**, Johns Hopkins University, is developing a model to identify populations of people who are at high risk for developing pancreatic cancer and should be regularly screened.
- **Dr. Diane Simeone**, University of Michigan, has developed a novel technology that can sort and collect a patient’s circulating tumor cells from their blood, and then grow them in the lab for therapeutic testing and genetic sequencing. She has been able to obtain critical information about a patient’s cancer from the cells collected, and the hope is that this information can accurately direct personalized care.
- **Dr. Mandar Muzumdar**, along with his mentor **Dr. Charles S. Fuchs**, Dana-Farber Cancer Institute, presented on the connection between obesity and pancreatic cancer, which is an area of great interest, as obesity is a modifiable risk factor for pancreatic cancer.
- **Dr. Hidde Ploegh**, MIT, has developed a novel noninvasive approach to imaging pancreatic cancer tumors when they are smaller than what the standard imaging methods can detect. He will now test this approach in pancreatic cancer models.

**Drug Targets**

- **Dr. Scott Lowe** and **Dr. Steven Leach**, both of Memorial Sloan Kettering Cancer Center, are using the “speedy mice” model, which develops pancreatic cancer more quickly than the conventional models, allowing therapies to be tested faster.
- **Dr. Julien Sage**, Stanford University, has identified a novel cancer-causing protein, which is a potential drug target, and he is testing the effects of drugs on this new target.
- **Dr. Tony Hunter**, Salk Institute for Biological Studies, is studying the “communication” between stromal cells and pancreatic cancer cells and has discovered that when a specific cancer-promoting signal is blocked, the mice with pancreatic cancer are living longer. Dr. Hunter is interested in exploring the clinical potential for this drug target.
- **Dr. Lewis Cantley**, Weill Cornell Medical College, is trying to better understand how a p53 mutation, the second most commonly mutated gene in pancreatic cancer, affects cells metabolism and cell signaling pathways that promote pancreatic cancer, and how they can be targeted therapeutically.
- **Dr. Channing Der**, UNC Chapel Hill, **Dr. Stephen Fesik**, Vanderbilt University Medical Center, **Dr. Frank McCormick**, UC San Francisco, and **Dr. Tyler Jacks**, MIT, are all conducting research on inhibiting KRas, the gene that is mutated in more than 90 percent of pancreatic cancer cases. In fact, Dr. McCormick has discovered a way to reverse the cancer-promoting signals of KRas, and his next step is to test this discovery in the clinic.

As Director of Research at the Foundation, my team and I are conducting an innovative program with organoids, which are three-dimensional cell culture systems that allow pancreatic cancer to be grown in the lab from human tissue. We are using organoids for personalized therapy, where we can closely examine the makeup of a patient’s pancreatic tumor and from there determine what treatments are most likely to work best. This research has exciting implications for the future of pancreatic cancer treatment.

Given the extensive research we have underway, we are confident that 2016 will be a year of considerable progress in moving closer to a better understanding of pancreatic cancer. As researchers, we are committed to pursuing different avenues to reach the same goal: finding a cure for this aggressive disease, and with your support, we will be able to conduct research to make that possible.

We look forward to updating you on our future progress.

Sincerely,

David Tuveson, M.D., Ph.D.
With deep gratitude and appreciation, The Lustgarten Foundation recognizes the late Patricia Galgan for her extremely generous donation of nearly $1 million from her estate to The Lustgarten Foundation. The Foundation is honored that Patricia left this meaningful gift, which will be used to advance the Foundation’s mission and fund critical pancreatic cancer research that will propel us towards even more promising scientific breakthroughs.

Patricia’s commitment to pancreatic cancer research ran deep. She lost her mother to this ravaging disease, and then, in late 2002, she lost her beloved husband Thomas after his courageous fight. Recognizing that something had to be done to more effectively combat the disease that prematurely took her loved ones, and wanting to make a lasting, positive impact on the pancreatic cancer landscape to honor her husband’s and her mother’s memories, Patricia added this legacy to her will, hoping to ensure that other families won’t have to endure the devastating loss that she has suffered from pancreatic cancer.

“I am proud that my mother’s selfless, giving spirit will live on through her gift to The Lustgarten Foundation, and I hope it motivates others to follow her example by contributing to causes that they feel strongly about supporting,” said Caroline Kispert, Patricia’s daughter. “My mother devoted her life to her family, and I’m sure she would be excited to see how much new research her gift has made possible.”

Legacy Society members have made gifts of all types and sizes, fulfilling their wishes to continue to support pancreatic research. To notify us of your intentions and discuss recognition opportunities or to learn more about planned gift options, contact Jennifer Grignoli, Director of Development, 516.803.1267 or jgrignol@cablevision.com.

We are so grateful for your generous contributions! Thanks to your participation in The Lustgarten Foundation’s Milestones & Momentum 2015 year-end campaign, we have raised more than $625,000, significantly surpassing our $500,000 goal for critical pancreatic cancer research. “The only way to fight against, and eventually beat, this disease is through extensive research, and I am confident that The Lustgarten Foundation’s researchers will make significant progress,” said Carol Whalen, who lost both her husband and her daughter to pancreatic cancer. “Thank you to everyone who joined me to support this important campaign to help make more research possible in 2016.”

With the incredible outpouring of support through this campaign, The Lustgarten Foundation can fund even more research focused on early detection, new treatments, and innovative methods of drug delivery. By joining together, we are one step closer to a cure!
The Lustgarten Foundation and Cablevision Systems Corporation, a leading media and telecommunications company, are partners in the curePC campaign, an award-winning public service campaign that raises awareness about pancreatic cancer and the Foundation’s efforts in the battle against this disease.

1 Team. 1 Mission.

The curePC campaign’s new series of online and print public service announcements (PSAs), “1 Team. 1 Mission,” highlights how everyone's contributions matter in the fight to beat pancreatic cancer. The series features the many team members - scientists, physicians, volunteers, caregivers and fundraisers - whose efforts help us make a difference. Visit curePC.org to view these inspirational team member stories and find out how you can join #TeamcurePC.

Pancreatic Cancer Awareness Month

In recognition of Pancreatic Cancer Awareness Month this past November, the curePC campaign launched a multifaceted online and social media initiative featuring easy ways to raise awareness and join #TeamcurePC. And on November 13, many Foundation supporters, including celebrities and members of the media, joined together for a special social media effort to mark World Pancreatic Cancer Day, reaching more than 12 million followers. Visit curePC.org to find out ways you can help to raise awareness.

STAY INFORMED WITH THE curePC CAMPAIGN

Online • www.curePC.org
YouTube • youtube.com/curePCcampaign
Twitter • @curePCcampaign
Pinterest • Pinterest/curePCcampaign
Instagram • Instagram.com/curePCcampaign

Help us spread the word about the fight against pancreatic cancer.

With the support of Cablevision, 100% of every dollar donated to The Lustgarten Foundation goes directly to pancreatic cancer research.
In September 2006, as Howard Ebert and his wife Ellen drove home from the doctor’s office after Howard received life-altering news, he felt like he was in the middle of a train tunnel, with the light from a huge freight train coming at him. That freight train was a pancreatic cancer diagnosis, and in that instant, Howard became one of the thousands of Americans diagnosed annually.

While Howard’s thoughts ran an emotional gamut, he wasn’t completely surprised by this devastating diagnosis. He knew he unfortunately had a family history of pancreatic cancer, which raised his risk of getting the disease. Witnessing the ravaging effects of pancreatic cancer firsthand within his family served to fuel his anxiety over his diagnosis.

Howard’s first experience with pancreatic cancer was 20 years ago, when his sister Marcia was diagnosed at only 46. All that could be done was palliative chemotherapy, as treatment options were extremely limited then. Marcia opted for quality of life and did not proceed with any invasive treatments. She passed away just six months later, leaving Howard shattered and shocked.

Three years later, Howard’s father received a similar diagnosis. While Howard was at the hospital with his father, a doctor suggested that he speak with a specialist about a possible genetic mutation in his family’s DNA, given that both his sister and father had the disease. He learned that he carried the BRCA mutation, making him more likely to develop the disease. He and his wife thoroughly researched physicians who were on the cutting-edge of screening procedures and early detection techniques, feeling that by proactively being monitored, he was taking a step towards safeguarding his health. “If you’re not an advocate for yourself or for your loved ones, you’re not going to succeed in your mission of being in control of your health,” said Howard.

Howard and Ellen’s diligent research and persistence eventually led him to a physician in New York who recommended an endoscopic ultrasound, a procedure that uses high-frequency sound waves to create detailed images of the digestive tract and nearby organs, including the pancreas, liver, and lymph nodes.

Howard began receiving yearly endoscopic ultrasounds, so that if a tumor did develop, it could be caught very early. This approach helped save his life. A two-centimeter tumor was discovered in 2006, when Howard had no symptoms, and he was forced to confront his own mortality.

Howard’s physician, Dr. John Chabot of Columbia Presbyterian Hospital in New York City, initially suggested that he undergo a Whipple procedure to remove part of the pancreas, a portion of the small intestine, and the gallbladder. However, after further analysis, Dr. Chabot instead recommended a complete pancreatectomy, or removal of the pancreas, which causes Type I diabetes. Despite this news, when Dr. Chabot said confidently that he could take care of his cancer, he and his wife felt like a huge boulder was lifting off of their shoulders, and Howard credits Dr. Chabot with saving his life.

Following a complicated surgery, Howard underwent six months of grueling chemotherapy treatments, and then, with only five weeks of chemotherapy left, he started having radiation concurrently to destroy the small metastases found in his lymph nodes. This aggressive regimen, managed by Dr. Chabot and Dr. William Sherman at Columbia Presbyterian Hospital, worked; by May 2007, Howard had finished treatment. In 2015, Howard celebrated eight years of being cancer-free. “My experience with pancreatic cancer changed my entire outlook on life. I’ve always been a glass half full kind of guy. But now the glass is half full with golden liquid;” he said.

Having cancer caused a fundamental shift in Howard’s thinking. He describes every day as a day to be enjoyed, to treat others well, be a better human being, and cherish family. He has become a more understanding, tolerant, loving person, and he credits his wife for being his rock through this journey and his three children and their spouses for being an incredible support system.

Howard became involved in The Lustgarten Foundation’s Long Island Pancreatic Cancer Research Walk, speaking to survivors and raising money, as a way to connect with others who share his experience as a pancreatic cancer patient and to honor the memory of his father and sister. Howard remembers the early walks, where there were only a few hundred attendees and little was known about the disease; now, the Long Island Pancreatic Cancer Research Walk, which he attends yearly, attracts 8,000 people. When the walk began, there was no survivors’ tent; now there can be 20 or 30 survivors attending the walk, which Howard describes as a powerful testament to the significant research progress being made – advancements in treatments including immunotherapy that might have helped his sister had they been available when she was diagnosed. “Organizations like The Lustgarten Foundation are bringing this disease from the shadows into the light and are working hard to change how many people and their families are affected,” he said.

Now, when Howard recounts his battle with this brutal, insidious disease, he tells people who are fighting for their lives like he did that the light at the end of the tunnel that he saw during that fateful day when he received his diagnosis was not a freight train coming at him. Rather, it was sunlight, and Howard believes that others will get through their fight against pancreatic cancer and see the sunlight at the end of the tunnel too – one step at a time, one day at a time, just like he did.
THE LUSTGARTEN FOUNDATION EXPANDS COLLABORATION WITH STAND UP TO CANCER (SU2C)

The Lustgarten Foundation is proud of its long-term collaboration with Stand Up To Cancer (SU2C) that now extends to three pancreatic cancer Dream Teams engaging several world-renowned scientists, with all projects involving clinical trials, leading to patient benefits in the three year funding cycle. To date, The Lustgarten Foundation has committed more than $14.5 million to this collaboration on Stand Up to Cancer’s four pancreatic cancer research teams. We believe strongly that combining our resources and best practices with SU2C strengthens our research program and will move us more quickly towards significant progress.

SU2C raises funds and brings together the best and brightest minds to accelerate research so that new therapies can get to patients quickly and potentially save lives. In May 2009, SU2C launched its Dream Team program, guided by SU2C’s key principles of collaboration, innovation, acceleration, and translational research, moving research from bench to bedside to make a significant impact on patients. Dream Team grants are awarded to multi-institutional groups of scientists, clinicians, technicians and other experts who work collaboratively to develop new therapies to benefit patients.

The first pancreatic cancer Dream Team was one of the five inaugural 2009 SU2C Dream Teams funded from the first SU2C telecast in 2008. Led by Daniel Von Hoff, M.D., TGen, and Craig Thompson, M.D., Memorial Sloan Kettering Cancer Center, the team initiated clinical trials to test new drug combinations. The team initially received $18 million in funding, and then received a $4 million supplement in 2013, including $2 million from The Lustgarten Foundation. Their research resulted in the discovery of the use of Abraxane with Gemcitabine, which became the first new drug combination therapy for pancreatic cancer as well as the standard of care for pancreatic cancer patients. Their research demonstrated that Abraxane combined with Gemcitabine increased one-year survival by 59 percent as compared to Gemcitabine alone. Progress of the SU2C-Lustgarten Foundation: Cutting the Fuel Supply to Pancreatic Cancer Dream Team can be seen at http://www.standup2cancer.org/progressreports/dream_team_progress_reports_pancreatic.

The SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team: Transforming Pancreatic Cancer to a Treatable Disease, initiated in 2014 in conjunction with the Fox Family Cancer Research Funding Trust, aims to develop new therapies using patients’ own immune cells to treat their cancers. This team was announced at the Annual Meeting of the American Association for Cancer Research (AACR). The AACR is SU2C’s Scientific Partner and grant administrator. It brings together leading individuals in the fields of immunotherapy, genetics, informatics, biostatistics, regulatory/clinical trials, cancer biology, and pathology from nine institutions, and Elizabeth M. Jaffee, M.D., Johns Hopkins University School of Medicine and Robert H. Vanderheide, M.D., D.Phil., University of Pennsylvania are co-leading the project. Their progress is reported here: http://www.standup2cancer.org/progressreports/dream_team_progress_reports_pancreatic_cancer_2.

In November 2015, the Stand Up To Cancer (SU2C)-Cancer Research UK (CRUK)-Lustgarten Foundation Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer, comprised of leading researchers from the United States and the United Kingdom, was announced at the AACR Molecular Targets meeting. This third Dream Team, led by Daniel Von Hoff, M.D., TGen, Ronald M. Evans, Ph.D., Salk Institute for Biological Studies, and Gerard I. Evan, Ph.D., University of Cambridge, focuses on reprogramming pancreatic cancer cells so that they become less aggressive and more sensitive to drugs and immunotherapies. Through this research, the Dream Team also hopes to improve the survival rate of pancreatic cancer patients, at least doubling the one-year survival in advanced pancreatic cancer patients from 35 percent to more than 70 percent, and to maintain remission in patients who have responded to treatment.

A pancreatic cancer translational research team will be formed under the direction of Jeffrey A. Drebin, M.D., Ph.D., University of Pennsylvania, to explore the effects of synthetic vitamin D (paricalcitol) on the immune cells that enter the pancreatic cancer tumor. Dr. Drebin and his team plan to conduct a clinical trial of Gemicitabine, Abraxane and paracalcitox, followed by treatment with an immunotherapy drug that is currently FDA-approved for certain types of melanoma and lung cancer.

Researchers engaged in these four pancreatic cancer teams recently convened at the Stand Up To Cancer Annual Scientific Summit in California, where they had the opportunity to share ideas and best practices and provide feedback and suggestions for further research. This Summit is particularly valuable in allowing researchers to share data, collaborate, and achieve the best value in their research to potentially change the lives of thousands of patients and their families.

The cancer landscape is changing rapidly, and because scientists can now target the genes and pathways that are involved in changing normal cells into cancerous cells, The Lustgarten Foundation, in collaboration with SU2C, believes we are on the verge of discovering new, advanced therapies that could be life-saving. Our pancreatic cancer Dream Teams are poised to play a critical role in these discoveries, and we look forward to providing updates and results on this innovative research.
NEW YORK CITY’S HOTTEST VENUES HOST TWO MAJOR FUNDRAISERS

We are pleased to highlight our two annual winter fundraisers of the year, the Holiday Rock & Roll Bash and Party with a Purpose. Together, these two events garnered more than $2.1 million for pancreatic cancer research that will move us towards a cure for this aggressive disease. Thank you to our dedicated event organizers, attendees, and generous supporters. Together, we will turn the promise of a cure into a reality.

15TH HOLIDAY ROCK & ROLL BASH
More Than $2 Million Raised

On December 16th, Cablevision Systems Corporation, The Madison Square Garden Company, and AMC Networks hosted the 15th annual Holiday Rock & Roll Bash to benefit The Lustgarten Foundation. Held for the first time at the exclusive Tao Downtown in New York City, the Bash attracted over 1,000 people and raised more than $2 million for the second consecutive year, with 100 percent of every dollar raised going directly to support pancreatic cancer research. Since its inception in 2001, the Holiday Rock & Roll Bash has raised $21 million for pancreatic cancer research.

During the program, Andrew and Jessica Lustgarten paid tribute to their late father Marc Lustgarten, who passed away from pancreatic cancer in 1999. They were joined by James Dolan, chief executive of Cablevision and executive chairman of The Madison Square Garden Company, who expressed his deep appreciation to the corporate sponsors whose generous donations to the Bash support the Foundation’s mission to find a cure. James Dolan and Cablevision Chairman Charles Dolan helped establish The Lustgarten Foundation in 1998 in honor of Mr. Lustgarten, who served as the former vice chairman of Cablevision and chairman of Madison Square Garden before he died from pancreatic cancer.

PARTY WITH A PURPOSE

Thank you to all of our supporters and friends who joined us for this year’s Party With A Purpose winter fundraiser! On January 21st, more than 200 people attended this 4th annual New York City cocktail reception, Party With A Purpose, held at famed hotspot 40/40 Club. The reception raised more than $112,000 for critical pancreatic cancer research, bringing the total raised since the event’s inception to more than $517,000. Guests enjoyed live entertainment, a mind reader, hors d’oeuvres and cocktails, including a signature purple cocktail to represent the universal color for pancreatic cancer awareness. The night was highlighted by a silent auction featuring incredible prizes, including show and sports tickets and memorabilia, golf outings and getaways, and restaurant gift certificates. Special thanks go out to our dedicated event committee for planning such a spectacular reception and auction! This event would also not have been possible without our presenting sponsor, Celgene, which has been an invaluable partner in our cause and is as committed as the Foundation is to eradicating this disease.

The Rockettes give an exclusive performance at the 15th annual Holiday Rock & Roll Bash to benefit The Lustgarten Foundation. Photo Credit: Avi Gerver

Committee members Kate Miller and Lauren Flick celebrate raising funds for pancreatic cancer research. Photo Credit: Melanie Einzig

Foundation supporters David and Debra Salmanson attend the 4th annual Party With A Purpose at the 40/40 Club in New York City. Photo Credit: Melanie Einzig

DJ Questlove, popular drummer of The Roots (house band for The Tonight Show Starring Jimmy Fallon), performs at Tao Downtown to a crowd of more than 1,000 Bash guests. Photo Credit: Avi Gerver

Committee members Kate Miller and Lauren Flick celebrate raising funds for pancreatic cancer research. Photo Credit: Melanie Einzig

Foundation supporters David and Debra Salmanson attend the 4th annual Party With A Purpose at the 40/40 Club in New York City. Photo Credit: Melanie Einzig

The Rockettes give an exclusive performance at the 15th annual Holiday Rock & Roll Bash to benefit The Lustgarten Foundation. Photo Credit: Avi Gerver
We are pleased to highlight just a few of the community events that have taken place last fall and extend our gratitude to all of those across the country who have joined our mission by coordinating activities for both fundraising and awareness in their own communities. Please visit www.lustgarten.org and visit the Events section to find an upcoming event in your area. We look forward to seeing you at one of our 300 community events scheduled for 2016!

Don’t see an event in your area? If you are interested in holding an event in your community, contact Susanne Igeri, Special Events Coordinator, 516.803.2339 or signeri@cablevision.com.

Bob Kochka 5K Run/Walk

On September 26th, the third annual Bob Kochka 5K Run/Walk was held in honor of long-time volunteer firefighter Bob Kochka, who passed away from pancreatic cancer in 2013. The event raised $15,000, bringing the total since this event started to more than $45,000. “We are honored to hold this event in memory of Bob’s fighting spirit and his commitment to his family, community, and fellow firefighters,” said John D’Amato, friend and fellow firefighter. “We know that funding research is the only way we’ll find a cure for pancreatic cancer.”

PANCREATIC CANCER RESEARCH
~ B. Michonski Strong ~ 5K Walk/Run

On September 26th, over 200 people participated in the third annual 5K walk/run in Skowhegan, Maine, raising $20,000 for The Lustgarten Foundation. Jodie Mosher-Towle co-organized the event in honor of her brother-in-law Brian Michonski, who passed away from pancreatic cancer in 2014. “Organizing this event in Brian’s honor brings our family, friends, the community, those honoring loved ones who lost their battle and pancreatic cancer survivors together to remember Brian and to continue fighting for more research, early detection techniques, and more treatment options, just as he wished,” said Jodie.

Claire Rose Bavaria Fundraiser for Pancreatic Cancer

On September 12th, the second annual Claire Rose Bavaria Fundraiser for Pancreatic Cancer was held, raising $26,000 for important research initiatives. The event was organized by Claire Rose’s husband, Dennis Bavaria, a long-time volunteer basketball coach, to honor her life and her battle with pancreatic cancer. He invited sponsors to make a donation for every foul shot out of 100 that a participant made. “I can’t think of a better way to honor my wife’s memory and the wonderful life she led than to continue raising awareness and research funding for this devastating disease that impacts so many families,” said Dennis.

Scramble for Shelly Golf Outing

Relatives of Shelly Bone held the first Scramble for Shelly golf outing and silent auction on October 10th, raising $14,000 for pancreatic cancer research. Shelly passed away from pancreatic cancer soon after the event following a year-long battle. “This event was the perfect opportunity to honor my mother’s life, and I know that every dollar we raised will make a difference for other families fighting this disease,” said Kristin Williams, Shelly’s daughter. Kristin is already planning a second golf outing for 2016.
COMMUNITIES WALK TO CELEBRATE THE PROMISE OF RESEARCH AND THE POTENTIAL FOR A CURE

Last year was record-setting for the Pancreatic Cancer Research Walk series, as our 31 walks attracted 18,000 participants and raised more than $3.9 million for urgently needed pancreatic cancer research. To date, our walk series has garnered nearly $31 million, and we are already off to an amazing start with the 2016 walks we’ve held so far, raising funding for cutting-edge research that is bringing us closer to a cure. We are pleased to announce that we are expanding our walk series, with six new walks slated for this year in Colorado, Ohio, Kentucky, Missouri, Texas, and California, and more than 35 walks in total.

Thank you to our dedicated volunteers who have so generously and graciously offered to organize and lead these events. For more information and to register, visit www.lustgarten.org.

Don’t see a walk near you? Learn how you can start a walk in your community. Contact Ann Walsh, Director of Events, 516.803.2419 or awalsh@cablevision.com.

NEW ENGLAND

Created in 2006, this year marked the 10th anniversary of the New England Pancreatic Cancer Research Walk, which takes place in Boston every year. Since its inception, this walk has raised over $3 million for pancreatic cancer research! Special thanks to event chair, Quinta Andersen.

WESTBOROUGH, MA & BRIDGEWATER, NJ

Maria Rydelek started the Bridgewater walk in 2009, to commemorate her mother’s life, and in 2010 her commitment continued when she started the Westborough, MA walk/run as well. Every spring and fall since, Maria organizes both events, and these walks have garnered nearly $593,000 since inception.

LONG ISLAND

More than 8,000 people participated in the 15th annual Long Island Pancreatic Cancer Research Walk at Jones Beach on October 11th, raising a ground-breaking $1.2 million for pancreatic cancer research. To date, this walk has raised more than $13 million since inception.

SYRACUSE, NY

2016 will mark the 11th year since Sue Hills and her family began the Syracuse Pancreatic Cancer Research Walk to honor her late husband Bert. Compounding her family’s heartbreak, Sue and Bert’s son Chip lost his life to the disease in 2015, giving this walk additional meaning and honoring both Bert’s and Chip’s legacy. Thanks to the Hills family’s unwavering commitment, this walk has raised more than $150,000 to date.

2016 Walks

WESTLAKE VILLAGE, CA • FT. MYERS, FL • PHOENIX, AZ • COLORADO SPRINGS, CO • WESTBOROUGH, MA • NEW YORK CITY, NY • WESTCHESTER, NY • BUTLER, OH • MILFORD, CT • CHICAGO, IL • MONMOUTH COUNTY, NJ • LIVERPOOL, NY • BROOKLYN, NY • LOUISVILLE, KY • CROMWELL, CT • NAPERVILLE, IL • HOWARD COUNTY, MD • PEMBROKE, OH • ST. LOUIS, MO • ALBANY, NY • CEDAR RAPIDS, IA • FREMONT, CA • LEHIGH VALLEY, PA • BOSTON, MA • SKOWHEGAN, ME • PARAMUS, NJ • FAIRFIELD COUNTY, CT • LONG ISLAND, NY • HANNIBAL, MO • NEW BRUNSWICK, NJ • DUTCHESS COUNTY, NY • PENNSAUKEN, NJ • DENVER, CO • SAN FRANCISCO, CA • EL PASO, TX • SILICON VALLEY, CA
### 2016 CALENDAR OF EVENTS

<table>
<thead>
<tr>
<th>MONTH</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>MARCH</td>
<td>Dance Away Pancreatic Cancer Gala</td>
<td>Albany, NY</td>
</tr>
<tr>
<td></td>
<td>New York City Half Marathon</td>
<td>New York, NY</td>
</tr>
<tr>
<td>APRIL</td>
<td>Westborough Pancreatic Cancer Research Walk</td>
<td>Westborough, MA</td>
</tr>
<tr>
<td></td>
<td>New York City Pancreatic Cancer Research Walk</td>
<td>New York, NY</td>
</tr>
<tr>
<td></td>
<td>Luauf for Lustgarten</td>
<td>Rochester, NY</td>
</tr>
<tr>
<td></td>
<td>Westchester Pancreatic Cancer Research Walk</td>
<td>Westchester, NY</td>
</tr>
<tr>
<td></td>
<td>Dash for Detection</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>MAY</td>
<td>Colorado Springs Pancreatic Cancer Research Walk</td>
<td>Colorado Springs, CO</td>
</tr>
<tr>
<td></td>
<td>Cincinnati Pancreatic Cancer Research Walk</td>
<td>Butler County, OH</td>
</tr>
<tr>
<td></td>
<td>Milford Pancreatic Cancer Research Walk</td>
<td>Milford, CT</td>
</tr>
<tr>
<td></td>
<td>Thomas Annunziata Memorial Golf Outing</td>
<td>Mount Kisco, NY</td>
</tr>
<tr>
<td>JUNE</td>
<td>Monmouth County Pancreatic Cancer Research Walk</td>
<td>Monmouth, NJ</td>
</tr>
<tr>
<td></td>
<td>Syracuse Pancreatic Cancer Research Walk</td>
<td>Liverpool, NY</td>
</tr>
<tr>
<td></td>
<td>Louisville Pancreatic Cancer Inaugural Research Walk</td>
<td>Louisville, KY</td>
</tr>
<tr>
<td></td>
<td>Brooklyn Pancreatic Cancer Research Walk</td>
<td>Brooklyn, NY</td>
</tr>
<tr>
<td></td>
<td>Richard and Jonathan Lewis Memorial Golf Outing</td>
<td>Glen Head, NY</td>
</tr>
<tr>
<td></td>
<td>Naperville Pancreatic Cancer Research Walk</td>
<td>Naperville, IL</td>
</tr>
<tr>
<td></td>
<td>Golfers Against Pancreatic Cancer</td>
<td>Scarsdale, NY</td>
</tr>
<tr>
<td>AUGUST</td>
<td>Cromwell 18-Hole Stroll</td>
<td>Cromwell, CT</td>
</tr>
<tr>
<td></td>
<td>Howard County Pancreatic Cancer Research Walk</td>
<td>Howard County, MD</td>
</tr>
<tr>
<td></td>
<td>Pemberville Pancreatic Cancer Research Walk</td>
<td>Pemberville, OH</td>
</tr>
<tr>
<td>SEPTEMBER</td>
<td>St. Louis Pancreatic Cancer Research Walk</td>
<td>St. Charles, MO</td>
</tr>
<tr>
<td></td>
<td>Albany Pancreatic Cancer Research Walk</td>
<td>Albany, NY</td>
</tr>
<tr>
<td></td>
<td>Appalachian Du/Triathlon to Fight Cancer</td>
<td>Neola, WV</td>
</tr>
<tr>
<td></td>
<td>Fremont Pancreatic Cancer Research Walk</td>
<td>Fremont, CA</td>
</tr>
<tr>
<td></td>
<td>Paramus Pancreatic Cancer Research Walk</td>
<td>Paramus, NJ</td>
</tr>
<tr>
<td>NOVEMBER</td>
<td>Cedar Rapids Pancreatic Cancer Research Walk</td>
<td>Marion, IA</td>
</tr>
<tr>
<td></td>
<td>Lehigh Valley Pancreatic Cancer Research Walk</td>
<td>Lehigh, PA</td>
</tr>
<tr>
<td>OCTOBER</td>
<td>New England Pancreatic Cancer Research Walk</td>
<td>Boston, NY</td>
</tr>
<tr>
<td></td>
<td>Long Island Pancreatic Cancer Research Walk</td>
<td>Wantagh, NY</td>
</tr>
<tr>
<td></td>
<td>Hannibal Pancreatic Cancer Research Inaugural Walk</td>
<td>Hannibal, MO</td>
</tr>
<tr>
<td></td>
<td>Dutchess County Pancreatic Cancer Research Walk</td>
<td>Poughkeepsie, NY</td>
</tr>
<tr>
<td>TBD</td>
<td>Silicon Valley Pancreatic Cancer Inaugural Research Walk</td>
<td>Silicon Valley, CA</td>
</tr>
<tr>
<td>NOVEMBER</td>
<td>Denver Pancreatic Cancer Research Walk</td>
<td>Denver, CO</td>
</tr>
<tr>
<td></td>
<td>Pennsauken Pancreatic Cancer Research Walk</td>
<td>Pennsauken, NJ</td>
</tr>
<tr>
<td>TBD</td>
<td>San Francisco Pancreatic Cancer Research Walk</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>TBD</td>
<td>El Paso Pancreatic Cancer Inaugural Research Walk</td>
<td>El Paso, TX</td>
</tr>
</tbody>
</table>

Be sure to check the calendar of events at www.lustgarten.org for updates.